AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish [Seeking Alpha]
AtaiBeckley Inc. (ATAI)
US:NASDAQ Investor Relations:
ir.atai.net.cn
Company Research
Source: Seeking Alpha
BPL-003 posted encouraging depression data and has the FDA's Breakthrough Therapy Designation. We also know BPL-003 is expected to enter Phase 3 in Q2 2026. VLS-01 and EMP-01 add pipeline depth. That's why I believe ATAI has a broader thesis beyond BPL-003 alone. Though that's the most advanced IP for now, which is why it's my main focus. Still, ATAI has no approved products, minimal revenue, and its valuation already reflects a meaningful premium (likely due to BPL-003's progress). Yevhenii Khil/iStock via Getty Images AtaiBeckley Inc. ( ATAI ) is a clinical-stage company that develops psychedelic therapies for treatment-resistant depression (TRD) and social anxiety disorder (SAD). It was formed after a combination of Atai Life Sciences and Beckley Psytech. ATAI's pipeline includes BPL-003 for TRD, which This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate
Show less
Read more
Impact Snapshot
Event Time:
ATAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATAI alerts
High impacting AtaiBeckley Inc. news events
Weekly update
A roundup of the hottest topics
ATAI
News
- BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 InitiationGlobeNewswire
- BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor DayGlobeNewswire
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA DecisionsPR Newswire
- AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 [Yahoo! Finance]Yahoo! Finance
- AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial [Yahoo! Finance]Yahoo! Finance
ATAI
Earnings
- 11/12/25 - Miss
ATAI
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 3
- 2/26/26 - Form 144
- ATAI's page on the SEC website